Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management

Abstract There is paucity of data regarding the diagnostic yield and safety of skin biopsies in patients with acute myeloid leukemia (AML), though skin eruptions are common in these patients. We evaluated 216 patients treated in our hemato-oncology unit at a tertiary medical center between 2007 and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tamar Berger, Shany Sherman, Lucille Hayman, Ofir Wolach, Adi Shacham-Abulafia, Pia Raanani, Oren Pasvolsky
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9f52b36024e84838be76d296b1edf098
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f52b36024e84838be76d296b1edf098
record_format	dspace
spelling	oai:doaj.org-article:9f52b36024e84838be76d296b1edf0982021-12-02T17:52:11ZSkin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management10.1038/s41598-021-91576-72045-2322https://doaj.org/article/9f52b36024e84838be76d296b1edf0982021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91576-7https://doaj.org/toc/2045-2322Abstract There is paucity of data regarding the diagnostic yield and safety of skin biopsies in patients with acute myeloid leukemia (AML), though skin eruptions are common in these patients. We evaluated 216 patients treated in our hemato-oncology unit at a tertiary medical center between 2007 and 2018 and identified 35 patients who underwent 37 skin biopsies. The majority of biopsies were performed during induction treatment for AML (n = 26, 70%), whereas the remainder of biopsies were done prior to induction initiation (n = 8, 22%) or during consolidation chemotherapy (n = 3, 8%). Pathology findings were inconclusive in 13 cases (35%), while diagnostic biopsies were positive for drug eruptions (24%), leukemia cutis (16%), infections (11%), reactive processes (8%) and Sweet syndrome (5.5%). In almost half of cases (16/37) tissue cultures were performed. Of those, only a quarter (4/16) were positive. Histopathology and tissue culture results altered immediate patient care in 3 cases (8%), yet information obtained from biopsies had potential to affect long term patient care in 8 additional cases (21.6%). Although most skin biopsies were performed while patients had severe thrombocytopenia and neutropenia, only one patient had a complication due to the biopsy (fever and local bleeding). With the limitation of a retrospective analysis, our study suggests that skin biopsies in patients treated for AML are relatively safe. Although biopsy results infrequently alter immediate patient management, long term effect on patient care expand the potential diagnostic yield of skin biopsies.Tamar BergerShany ShermanLucille HaymanOfir WolachAdi Shacham-AbulafiaPia RaananiOren PasvolskyNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tamar Berger Shany Sherman Lucille Hayman Ofir Wolach Adi Shacham-Abulafia Pia Raanani Oren Pasvolsky Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
description	Abstract There is paucity of data regarding the diagnostic yield and safety of skin biopsies in patients with acute myeloid leukemia (AML), though skin eruptions are common in these patients. We evaluated 216 patients treated in our hemato-oncology unit at a tertiary medical center between 2007 and 2018 and identified 35 patients who underwent 37 skin biopsies. The majority of biopsies were performed during induction treatment for AML (n = 26, 70%), whereas the remainder of biopsies were done prior to induction initiation (n = 8, 22%) or during consolidation chemotherapy (n = 3, 8%). Pathology findings were inconclusive in 13 cases (35%), while diagnostic biopsies were positive for drug eruptions (24%), leukemia cutis (16%), infections (11%), reactive processes (8%) and Sweet syndrome (5.5%). In almost half of cases (16/37) tissue cultures were performed. Of those, only a quarter (4/16) were positive. Histopathology and tissue culture results altered immediate patient care in 3 cases (8%), yet information obtained from biopsies had potential to affect long term patient care in 8 additional cases (21.6%). Although most skin biopsies were performed while patients had severe thrombocytopenia and neutropenia, only one patient had a complication due to the biopsy (fever and local bleeding). With the limitation of a retrospective analysis, our study suggests that skin biopsies in patients treated for AML are relatively safe. Although biopsy results infrequently alter immediate patient management, long term effect on patient care expand the potential diagnostic yield of skin biopsies.
format	article
author	Tamar Berger Shany Sherman Lucille Hayman Ofir Wolach Adi Shacham-Abulafia Pia Raanani Oren Pasvolsky
author_facet	Tamar Berger Shany Sherman Lucille Hayman Ofir Wolach Adi Shacham-Abulafia Pia Raanani Oren Pasvolsky
author_sort	Tamar Berger
title	Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
title_short	Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
title_full	Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
title_fullStr	Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
title_full_unstemmed	Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
title_sort	skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9f52b36024e84838be76d296b1edf098
work_keys_str_mv	AT tamarberger skinbiopsiesinacutemyeloidleukemiapatientsundergoingintensivechemotherapyaresafeandeffectpatientmanagement AT shanysherman skinbiopsiesinacutemyeloidleukemiapatientsundergoingintensivechemotherapyaresafeandeffectpatientmanagement AT lucillehayman skinbiopsiesinacutemyeloidleukemiapatientsundergoingintensivechemotherapyaresafeandeffectpatientmanagement AT ofirwolach skinbiopsiesinacutemyeloidleukemiapatientsundergoingintensivechemotherapyaresafeandeffectpatientmanagement AT adishachamabulafia skinbiopsiesinacutemyeloidleukemiapatientsundergoingintensivechemotherapyaresafeandeffectpatientmanagement AT piaraanani skinbiopsiesinacutemyeloidleukemiapatientsundergoingintensivechemotherapyaresafeandeffectpatientmanagement AT orenpasvolsky skinbiopsiesinacutemyeloidleukemiapatientsundergoingintensivechemotherapyaresafeandeffectpatientmanagement
_version_	1718379243798265856

Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management

Ejemplares similares